BTK and primary central nervous system lymphoma: Given the superior BBB penetration of JDB175 compared to currently approved BTK inhibitors, it is essential to evaluate the activity of BTK inhibitors in combination with these agents in future clinical trials for the inhibition of CNS lymphoma.